Enrylaze
What Enrylaze is used for
Enrylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL) in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to E. coli-derived asparaginase.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Enrylaze
- Active substance
- crisantaspase
- Disease area
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Medicine group
- Antineoplastic agents
- ATC code
- L01XX02
- Marketing authorisation holder
- Jazz Pharmaceuticals Ireland Limited
- Authorised in the EU since
- 2023
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Enrylaze used for?
Enrylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL) in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to E. coli-derived asparaginase.
What is the active substance in Enrylaze?
Enrylaze contains crisantaspase.
Who makes Enrylaze?
The EU marketing authorisation holder is Jazz Pharmaceuticals Ireland Limited.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU